The following characteristics help counter AMR development and issues related to the conventional pipeline:

• Development costs should be about 1000 times less ($1 million versus $1 billion).
• Having multiple mechanisms of action would help counter AMR.
• Many effective, cheap, low toxicity compounds with well defined composition would be needed to achieve the above.
• Plant based compounds, ie. botanicals could achieve the above. 
• If the product were topical only, its safety profile would be further enhanced, decreasing therapeutic and commercial risk.
• Microbial mechanisms of achieving resistance would have to be specifically countered.
• The product would require particularly strong activity against the key pathogenic species. 
• A non-prescription OTC (over the counter) pathway would be preferred.
• If AMR development could be minimised, the product could be widely used, increasing commercial profitability and longevity. 
• If the product were non-conventional, and synergies with conventional antibiotics could be established, this would greatly increase therapeutic and commercial value. 
• Concurrent activity against pathogenic fungi would be highly advantageous in treating mixed infections, without the delay and cost of laboratory micro testing. 
• The above being achieved would constitute a new antibiotic class.